
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Epidemiology, Natural History, and Treatment of Eosinophilic Gastrointestinal Diseases</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Epidemiology, Natural History, and Treatment of Eosinophilic Gastrointestinal Diseases</strong></summary>
            <div>
                <ul><li>- <b>Journal:</b> Gastroenterology</li><li>- <b>Publication Date:</b> Available online 25 November 2025</li><li>- <b>DOI:</b> https://doi.org/10.1053/j.gastro.2025.09.030</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the histologic remission rate for a <b>one-food elimination diet (OFED)</b> in EoE?</li><li>- What percentage of patients with EoE develop fibrosis for each year of <u>undiagnosed active disease</u>?</li><li>- What is the histologic diagnostic cutoff for <b>eosinophilic gastritis (EoG)</b>?</li><li>- What is the most frequent adverse event associated with <b>Swallowed Topical Corticosteroids (STCs)</b> in EoE treatment?</li><li>- What percentage of patients in remission from EoE after treatment with <b>budesonide orodispersible tablet (BOT)</b> had a recurrence 48 weeks after stopping treatment?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Introduction & Definitions</strong></summary>
            <div>
                <ul><li>- <b>Eosinophilic gastrointestinal diseases (EGIDs)</b> are chronic, immune-mediated disorders characterized by pathologic infiltration of eosinophils in the GI tract.</li><li>- Pathophysiology involves <u>type 2 immunity</u> and <u>allergen-driven</u> inflammatory reactions.</li><li>- EGIDs are divided into <b>Eosinophilic Esophagitis (EoE)</b>, restricted to the esophagus, and <b>non-EoE EGIDs</b>, affecting other GI segments.</li></ul>
                
        <details>
            <summary><strong>Clinical Presentation: <b>EoE</b></strong></summary>
            <div>
                <ul><li>- <b>Adults:</b> Typically present with <u>dysphagia</u> and episodes of <u>food bolus impaction</u>.</li><li>- <b>Adaptive Behaviors (Adults):</b> Drinking water, cutting food into small pieces, eating slowly, and avoiding sticky foods.</li><li>- <b>Children:</b> Commonly report nonspecific upper GI symptoms, food refusal, picky eating, and fear of food.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Presentation: <b>Non-EoE EGIDs</b></strong></summary>
            <div>
                <ul><li>- Symptoms are heterogenous and depend on the location of inflammation.</li><li>- Common symptoms include <u>abdominal pain/cramping</u>, diarrhea, nausea/vomiting, bloating, anorexia/weight loss, and blood in the stool.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Nomenclature & Diagnostic Criteria</strong></summary>
            <div>
                <ul><li>- A 2022 consensus established <b>"EGID"</b> as the umbrella term.</li><li>- EGIDs are subdivided into <b>EoE</b> and <b>non-EoE EGIDs</b>.</li><li>- Non-EoE EGIDs are named by location: Eosinophilic Gastritis (<b>EoG</b>), Eosinophilic Enteritis (<b>EoN</b>), and Eosinophilic Colitis (<b>EoC</b>).</li></ul>
                
        <details>
            <summary><strong><b>EoE</b>: Diagnostic Criteria</strong></summary>
            <div>
                <ul><li>- Diagnosis requires a combination of three key elements:</li><li>- 1. Symptoms of <u>esophageal dysfunction</u>.</li><li>- 2. Histology showing at least <q><b>15 eosinophils per high-power field</b> (eos/hpf)</q> on esophageal biopsy.</li><li>- 3. Exclusion of competing causes of esophageal eosinophilia.</li></ul>
                
        <details>
            <summary><strong>Severity Assessment</strong></summary>
            <div>
                <ul><li>- The <b>Index of Severity for EoE (I-SEE)</b> is used at diagnosis and for longitudinal follow-up.</li><li>- It assesses three domains: symptoms/complications, inflammatory features, and fibrostenotic features.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Non-EoE EGIDs</b>: Diagnostic Criteria</strong></summary>
            <div>
                <ul><li>- The diagnostic process is more challenging than for EoE.</li><li>- Approach involves attributing GI symptoms to disease location, finding pathologically elevated eosinophils on biopsy, and excluding other causes of GI eosinophilia.</li></ul>
                
        <details>
            <summary><strong>Diagnostic Challenges</strong></summary>
            <div>
                <ul><li>- Symptoms are often <u>nonspecific</u>.</li><li>- Inflammation can involve <b>muscular</b> and <b>serosal</b> layers, not just the mucosa.</li><li>- Eosinophils are normally present in the stomach, small intestine, and colon, unlike the esophagus.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Histologic Thresholds for Pathologic Eosinophilia</strong></summary>
            <div>
                <ul><li>- <b>Stomach:</b> <q><u>≥30 to 40 eos/hpf</u></q></li><li>- <b>Duodenum:</b> <q><u>≥50 to 60 eos/hpf</u></q></li><li>- <b>Terminal Ileum:</b> <q><u>≥60 eos/hpf</u></q></li><li>- <b>Cecum & Right Colon:</b> <q><u>≥100 eos/hpf</u></q></li><li>- <b>Left Colon:</b> <q><u>≥60 eos/hpf</u></q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Common Pitfalls Leading to Diagnostic Delay</strong></summary>
            <div>
                <ul><li>- Lack of recognition by clinicians and pathologists.</li><li>- Collection of too few biopsy samples.</li><li>- Lack of eosinophil count quantification on pathology reports.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Global Epidemiology</strong></summary>
            <div>
                <ul><li>- The epidemiology of EGIDs, particularly EoE, is evolving rapidly with a continuous increase in incidence and prevalence over the past 30 years.</li></ul>
                
        <details>
            <summary><strong><b>Eosinophilic Esophagitis (EoE)</b></strong></summary>
            <div>
                <ul><li>- Incidence and prevalence are markedly and continually increasing worldwide, with no plateau observed.</li></ul>
                
        <details>
            <summary><strong>Incidence & Prevalence Rates</strong></summary>
            <div>
                <ul><li>- <b>2017-2022 Global Estimate:</b></li><li>- Incidence: <q>6.81 per 100,000</q></li><li>- Prevalence: <q>74.42 per 100,000</q></li><li>- <b>2037 Projection:</b></li><li>- Incidence: <q>12.67 per 100,000</q></li><li>- Prevalence: <q>110.82 per 100,000</q></li><li>- <b>2022 US Claims Data:</b> Prevalence estimated at <q><u>142.5 per 100,000</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Underdiagnosis & Diagnostic Delay</strong></summary>
            <div>
                <ul><li>- EoE may be significantly underdiagnosed (the "tip of the iceberg").</li><li>- Patients often experience symptoms for <q><b>5 to 10 years</b></q> before diagnosis.</li><li>- A study noted <q>>700,000</q> emergency visits for dysphagia/impaction in males <40 without an EoE code, suggesting a large undiagnosed population.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prevalence in Special Populations</strong></summary>
            <div>
                <ul><li>- Endoscopy for any indication: <q><b>6% to 7%</b></q></li><li>- Endoscopy for dysphagia: <q><u>up to 25%</u></q></li><li>- Food bolus impaction: <q><b>≥50%</b></q></li><li>- Refractory reflux symptoms: <q>1% to 20%</q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Associated Atopic & Other Conditions</strong></summary>
            <div>
                <ul><li>- Having food allergies increases odds of EoE by <q><b>9-fold</b></q>.</li><li>- Relative increase in EoE over general population:</li><li>- Asthma, eczema, seasonal allergies: <q>~5-fold</q></li><li>- Food allergies: <q>>15-fold</q></li><li>- Family history: <q><b>2% to 3%</b></q> risk between first-degree relatives.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk Factors</strong></summary>
            <div>
                <ul><li>- The rapid rise implicates changing environmental factors.</li></ul>
                
        <details>
            <summary><strong>Environmental & Geographic Factors</strong></summary>
            <div>
                <ul><li>- Decreasing prevalence of <b>Helicobacter pylori</b>.</li><li>- Geographic factors: low population density, arid/cold climates.</li><li>- Poor environmental quality (especially water), heavy metals, proximity to large farms, airborne particulate matter.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Early Life Exposures</strong></summary>
            <div>
                <ul><li>- <b>Risk Factors:</b> Cesarean delivery, neonatal ICU admission, antibiotic exposure (infant and maternal), acid suppressant use in infancy.</li><li>- <b>Protective Factor:</b> Having furred pets in the home.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Gene-Environment Interaction</strong></summary>
            <div>
                <ul><li>- Breastfeeding was protective against EoE only in children with the risk allele in the <q><b>calpain 14 (CAPN14)</b></q> gene.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Barrier Defect Hypothesis</strong></summary>
            <div>
                <ul><li>- EoE may be driven by a defective esophageal epithelial barrier.</li><li>- Environmental detergents (e.g., sodium dodecyl sulfate in toothpaste) may disrupt this barrier, as shown in animal models.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Non-EoE EGIDs</b></strong></summary>
            <div>
                <ul><li>- Far less is known about the epidemiology of non-EoE EGIDs, which are considered rare diseases.</li></ul>
                
        <details>
            <summary><strong>Prevalence & Incidence</strong></summary>
            <div>
                <ul><li>- <b>US Prevalence (2022):</b></li><li>- EoG/EGE: <q>6.6 per 100,000</q></li><li>- EoC: <q>3.0 per 100,000</q></li><li>- Unlike EoE, a male predominance is <u>not</u> observed.</li><li>- Overlap is common: <q>more than one-third</q> of patients have >1 GI segment involved.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Underdiagnosis & Risk Factors</strong></summary>
            <div>
                <ul><li>- Diagnostic delay of <q><b>3 to 5 years</b></q> or longer is reported.</li><li>- Risk factors are poorly understood but include high rates of concomitant atopic conditions, family predisposition, and an inverse association with H. pylori.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Natural History</strong></summary>
            <div>
                <ul><li>- The natural history differs between EoE and non-EoE EGIDs, with EoE being characteristically chronic and progressive.</li></ul>
                
        <details>
            <summary><strong><b>Eosinophilic Esophagitis (EoE)</b></strong></summary>
            <div>
                <ul><li>- EoE is a <b>chronic</b> disease and is <b>progressive</b> in many patients.</li></ul>
                
        <details>
            <summary><strong>Progression & Fibrostenosis</strong></summary>
            <div>
                <ul><li>- In untreated adults, <q><b>97%</b></q> have persistent dysphagia at ~7 years follow-up.</li><li>- Risk of progression to fibrostenotic disease is time-dependent.</li><li>- There is a <q><u><b>5% risk</b> of developing fibrosis for each year</u></q> of undiagnosed active disease.</li><li>- Gaps in care of <q><b>2 years or more</b></q> are associated with developing fibrostenosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Remission & Recurrence</strong></summary>
            <div>
                <ul><li>- Spontaneous disease remission is uncommon (<q><b>0.5%</b></q> in a large pediatric study).</li><li>- Disease almost universally recurs when effective treatment is withdrawn.</li><li>- After stopping <b>budesonide orodispersible tablet (BOT)</b>, <q><u><b>99%</b></u></q> of patients had clinical and histologic recurrence by 48 weeks.</li></ul>
                
        <details>
            <summary><strong>Recurrence after other treatments</strong></summary>
            <div>
                <ul><li>- After stopping topical steroids, median time to symptom recurrence was <q><b>244 days</b></q>.</li><li>- After <b>budesonide oral suspension (BOS)</b> withdrawal, <q><b>78%</b></q> had histologic recurrence by week 36.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Non-EoE EGIDs</b></strong></summary>
            <div>
                <ul><li>- Data are less robust, but three main patterns of disease course have been identified based on intestinal layer involvement (mucosal, muscle, serosal).</li></ul>
                
        <details>
            <summary><strong>Identified Disease Courses</strong></summary>
            <div>
                <ul><li>- A longitudinal study identified three different courses over a median of 13.1 years:</li><li>- <b>Single flare:</b> <q>42%</q> of patients</li><li>- <b>Recurring course:</b> <q>37%</q> of patients</li><li>- <b>Continuous course:</b> <q>21%</q> of patients</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Disease Course Patterns</strong></summary>
            <div>
                <ul><li>- A more recent study identified courses as:</li><li>- <b>Continuous:</b> Unchanged histology/symptoms for ≥6 months.</li><li>- <b>Relapsing:</b> Remitting histology or relapsing symptoms for ≥6 months.</li><li>- <b>Progressive:</b> Increasing histologic or symptomatic burden for ≥6 months.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- Treatment strategies and available evidence differ significantly between EoE and non-EoE EGIDs.</li></ul>
                
        <details>
            <summary><strong>Treatment of <b>Eosinophilic Esophagitis (EoE)</b></strong></summary>
            <div>
                <ul><li>- Treatment endpoints include improvement of symptoms, endoscopic findings, inflammation, and quality of life.</li><li>- <b>Histologic Remission:</b> <q><u><15 eos/hpf</u></q></li><li>- <b>Endoscopic Remission:</b> <q>EREFS score of ≤2</q></li></ul>
                
        <details>
            <summary><strong><b>Proton Pump Inhibitors (PPIs)</b></strong></summary>
            <div>
                <ul><li>- Common first-line, off-label treatment.</li><li>- <b>Efficacy (Meta-analysis):</b></li><li>- Clinical (symptom) response: <q><b>65%</b></q></li><li>- Histologic remission (<15 eos/hpf): <q><b>45.4%</b></q></li><li>- <b>Dosing:</b> Twice-daily treatment is more effective (<q>51.7%</q> remission) than once-daily (<q>28.3%</q>).</li><li>- <b>Maintenance:</b> <q>68.2%</q> of patients maintain remission on a half-dose.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Swallowed Topical Corticosteroids (STCs)</b></strong></summary>
            <div>
                <ul><li>- A first-line therapy for induction and maintenance of remission.</li><li>- Approved formulations: <b>budesonide orodispersible tablet (BOT)</b> in Europe, <b>budesonide oral suspension (BOS)</b> in the US.</li></ul>
                
        <details>
            <summary><strong>Efficacy & Safety</strong></summary>
            <div>
                <ul><li>- <b>Induction Remission Rates:</b></li><li>- BOT: <q>57.6%</q></li><li>- BOS: <q>>50%</q></li><li>- <b>Maintenance:</b> Efficacy sustained in <q>~80%</q> of patients for up to 48 weeks.</li><li>- <b>Long-term:</b> <q>20% to 40%</q> may lose response over 3-4 years.</li><li>- <b>Most Frequent Adverse Event:</b> <q><u>Esophageal candidiasis</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Monoclonal Antibodies</b></strong></summary>
            <div>
                <ul><li>- Several biologics failed to meet endpoints, indicating eosinophil depletion alone is not sufficient for remission.</li></ul>
                
        <details>
            <summary><strong><b>Dupilumab</b> (Anti-IL4/IL13)</strong></summary>
            <div>
                <ul><li>- The only biologic currently approved for EoE in the US and Europe.</li><li>- Approved for patients aged <q>≥1 year</q>, weighing <q>≥15 kg</q>.</li><li>- <b>Efficacy (Adolescents/Adults):</b> <q>~60%</q> clinico-histologic remission at week 24.</li><li>- <b>Efficacy (Children 1-11 years):</b> <q>68%</q> histologic remission by week 16.</li><li>- <b>Recommendation:</b> Second-line after PPI/STC failure, or first-line in patients with other type 2 comorbidities.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Food Elimination Diets (FEDs)</b></strong></summary>
            <div>
                <ul><li>- EoE is a delayed-type hypersensitivity; allergy tests (skin prick, patch, serum IgE) are <u>not recommended</u> to identify food triggers.</li><li>- Empiric elimination of common triggers is the recommended strategy.</li></ul>
                
        <details>
            <summary><strong>Efficacy of Empiric FEDs</strong></summary>
            <div>
                <ul><li>- Histologic remission rates from meta-analysis:</li><li>- <b>One-Food (OFED - milk):</b> <q>46.7%</q></li><li>- <b>Two-Food (TFED - milk, wheat):</b> <q>44.3%</q></li><li>- <b>Four-Food (FFED - milk, wheat, egg, soy):</b> <q>54.7%</q></li><li>- <b>Six-Food (SFED - FFED + nuts, seafood):</b> <q>63.9%</q></li><li>- <b>Recommendation:</b> Start with the least restrictive diet (e.g., OFED/milk elimination) and step-up if no response.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment of <b>Non-EoE EGIDs</b></strong></summary>
            <div>
                <ul><li>- Management is challenging due to a lack of established endpoints, validated outcomes, and approved treatments.</li><li>- Evidenceis currently based on low-quality evidence from small case series and observational studies.</li></ul>
                
        <details>
            <summary><strong><b>Corticosteroids</b></strong></summary>
            <div>
                <ul><li>- Corticosteroids are the <u>mainstay of treatment</u> for non-EoE EGIDs.</li></ul>
                
        <details>
            <summary><strong>Systemic Corticosteroids</strong></summary>
            <div>
                <ul><li>- <b>Prednisone</b> is used at doses up to <q>60 mg per day</q>, then tapered over 4 to 6 weeks.</li><li>- Induces remission with response rates ranging from <q><b>50% to 100%</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Topical Corticosteroids</strong></summary>
            <div>
                <ul><li>- <b>Enteral release budesonide</b> (doses <q>0.25 mg to 9 mg per day</q>) offers an alternative with fewer systemic adverse events.</li><li>- Capsules can be modified to target specific GI segments (stomach, proximal small bowel, distal small bowel/colon).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Food Elimination Diets (FEDs)</b></strong></summary>
            <div>
                <ul><li>- Evidence is heterogeneous but supports a role for dietary management.</li></ul>
                
        <details>
            <summary><strong>Elemental Diet</strong></summary>
            <div>
                <ul><li>- In children, elemental diets led to clinical remission in <q><b>76%</b></q> and histologic remission in <q><b>83%</b></q>.</li><li>- A recent prospective trial in adults with EoG/EoN showed a 6-week elemental diet achieved <q><u>100% histologic remission</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Empiric & SFED</strong></summary>
            <div>
                <ul><li>- Empiric FEDs (milk, wheat, etc.) showed symptomatic improvement in <q><b>63%</b></q> of patients.</li><li>- Six-Food Elimination Diet (SFED) or 7-FED showed symptomatic improvement in <q><b>85%</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Monoclonal Antibodies</b></strong></summary>
            <div>
                <ul><li>- Several biologics have been studied, but none are currently approved for non-EoE EGIDs.</li></ul>
                
        <details>
            <summary><strong>Failed/Discontinued Trials</strong></summary>
            <div>
                <ul><li>- <b>Lirelimab (anti-Siglec-8):</b> Phase 3 failed to show symptom improvement despite histologic response (<q>85%</q> of patients).</li><li>- <b>Benralizumab:</b> Phase 3 failed to demonstrate symptom improvement in EoG.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Agents with Ongoing Investigation/Data</strong></summary>
            <div>
                <ul><li>- <b>Dupilumab:</b> Phase 2 RCT in EoG showed histologic/endoscopic improvement. Observational studies report positive symptom outcomes. A new RCT is ongoing.</li><li>- <b>Cendakimab (anti-IL13):</b> A Phase 3 RCT in Japan demonstrated clinical efficacy in EGE.</li><li>- <b>Vedolizumab:</b> Has shown efficacy in small case series of refractory patients.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Nonsteroidal, Nonbiologic Treatments</strong></summary>
            <div>
                <ul><li>- Includes PPIs, mast cell stabilizers (cromolyn, ketotifen), leukotriene inhibitors (montelukast), and immunomodulators (azathioprine).</li><li>- Results are variable and based on case reports/series.</li><li>- Guidelines state there is <u>insufficient data</u> to recommend for or against their use.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Emerging Treatments for EGIDs</strong></summary>
            <div>
                <ul><li>- Several novel therapeutic strategies are under investigation for both EoE and non-EoE EGIDs.</li></ul>
                
        <details>
            <summary><strong>Novel Topical Corticosteroid Delivery Systems</strong></summary>
            <div>
                <ul><li>- <b>ESO-101:</b> Capsule with a mucoadhesive film of mometasone furoate.</li><li>- <b>EP-104GI:</b> Long-acting fluticasone injected into the esophagus.</li><li>- <b>APT-1011:</b> Fluticasone orodispersible tablet.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Monoclonal Antibodies</strong></summary>
            <div>
                <ul><li>- <b>Cendakimab</b> (anti-IL13)</li><li>- <b>Tezepelumab</b> & <b>Solrikitug</b> (anti-TSLP)</li><li>- <b>Barzolvolimab</b> (anti-KIT)</li><li>- <b>CALY-002</b> (anti-IL15)</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Small Molecules & Other Agents</strong></summary>
            <div>
                <ul><li>- Immune-resetting peptide 1104</li><li>- Etrasimod</li><li>- Potassium-competitive acid blockers</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Knowledge Gaps & Future Directions</strong></summary>
            <div>
                <ul><li>- Significant gaps remain in understanding and managing EGIDs, highlighting key areas for future research.</li></ul>
                
        <details>
            <summary><strong><b>Eosinophilic Esophagitis (EoE)</b></strong></summary>
            <div>
                <ul><li>- <b>Key Gaps:</b></li><li>- Diagnostic delay remains an issue.</li><li>- Mechanisms of environmental/early life risk factors are unknown.</li><li>- Lack of predictors for treatment response and disease progression.</li><li>- No head-to-head drug comparisons to establish a treatment hierarchy.</li></ul>
                
        <details>
            <summary><strong>Future Research Directions for EoE</strong></summary>
            <div>
                <ul><li>- Study <u>endotypes and phenotypes</u> to personalize therapy.</li><li>- Develop <b>noninvasive or minimally invasive monitoring strategies</b> (e.g., blood-based, esophageal string/sponge tests) to make management less cumbersome.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Non-EoE EGIDs</b></strong></summary>
            <div>
                <ul><li>- <b>Key Gaps:</b></li><li>- Diseases are rare and possibly underdiagnosed.</li><li>- Pathophysiology, risk factors, and pathogenesis are largely unknown.</li><li>- Natural history data needs corroboration.</li><li>- <u>No approved treatments</u> are available.</li></ul>
                
        <details>
            <summary><strong>Future Research Directions for Non-EoE EGIDs</strong></summary>
            <div>
                <ul><li>- Adherence to new nomenclature and guidelines is crucial for better disease characterization.</li><li>- Prospective studies are needed to validate natural history and guide therapy development.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
